Cerebrolysin (FPF-1070) is a unique neuropeptide preparation from enzymatic breakdown of purified porcine brain proteins.
Composition
Cerebrolysin is not a single peptide but a complex mixture:
- ~25% low molecular weight peptides (<10,000 Da)
- ~75% free amino acids
Contains active fragments mimicking BDNF, NGF, GDNF, and CNTF.
Mechanism of Action
Neurotrophic Factor Modulation
- Upregulates VEGF, BDNF, IGF-1, NGF
- Downregulates TNF-α
Neuroprotection
- Reduces amyloid plaque formation
- Inhibits calpain, caspase-3
- Modulates Bcl-2/Bax balance
Clinical Evidence
Alzheimer's Disease
Meta-analysis of 6 RCTs: beneficial effect and favorable benefit-risk ratio in mild-to-moderate AD. 39 clinical trials, 3,600+ patients.
Stroke
Mixed results. Some Asian studies showed benefits, but Cochrane-style reviews found no mortality benefit.
Vascular Dementia
Positive effects reported for cognitive impairment.
Regulatory Status
- Approved: Many European and Asian countries
- NOT Approved: United States (FDA)
Administration
IV or IM injection. Stroke: 30-50 mL IV daily. Dementia: 10-30 mL IV/IM.